Overview

Special Combination of OBP-301 and Pembrolizumab

Status:
Active, not recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

This is multicenter, open-label Phase I study to exploratively evaluate the efficacy and safety of OBP-301 in combination with Pembrolizumab in patients with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Toshihiko Doi

Collaborators:

Merck Sharp & Dohme Corp.
Oncolys BioPharma Inc

Treatments:

Pembrolizumab